U.S. Markets close in 6 hrs 19 mins

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
20.16-0.05 (-0.25%)
As of 9:41AM EDT. Market open.
People also watch
  • interesting price action of late. United contract renewal and Vectra coverage news to come. If both are positive we will see the shorts retreat at speed
  • News today was expected
  • down on low volume. Sign the shorts are leaving
  • A week ago, I called the $23 pps. MYGN is one of the most heavily shorted stocks on the stock exchange. Major short squeeze could push this stock to $28 in no time!
  • do the math
  • current run rate of 200,000 plus tests a year.
  • they beat savagely low expectations. stock is clear to trade at $22 or $23. very impressive, not. they dont really have much of a plan do they? hence the flat quarter in q2. in a down market, it could re-test $15.
  • Easing its way back to 26 with news of United contract renewal being the next upward catalyst to $34 by year end IMHO
  • Genesight potential is massive.
  • Just listened to the CC. Pretty much what was needed, and what would be expected at this stage of playing out a "dumpster year." Didn't notice much about growth initiatives that are definitely there (esp kit-based tests). Lots of fiddly accounting changes. I now expect a pretty good August call with a forecast that sounds slightly optimistic. The plan, of course, is that they hope to beat the optimistic-sounding forecast by ever-increasing amounts. That's what Myriad used to do. and 15+ months after last August's CC, analysts may easily be receptive. I'd like to have a Shareholders' Day sometime in the next year, but nobody's listening.
  • Shorts reexamining position this morning $22 by end of day
  • Upgrades coming quickly after their good clients get in and the shorts get out.
  • Lift off and back to the thirties by September 2017 IMHO
  • My guess is that MYGN is due for a pullback in the short-run. I started receiving notifications from aawesomestocks the other week and so far they have presented interesting new trade ideas.
  • It appears that the PARP inhibitor Rubraca (available now under acccelerated approval) will have a need for BRCA testing on label. The manufacturer is specifying Incyte's test for germ-line mutation, and the drug has been added to Myriad's FDA filings for somatic BRCA mutation testing.

    It's complicated, but it's good news.
  • European reimbursement also key growth market. Getting Genesight into the PC market also key
  • With earnings approaching: I expect meet, but not beat forecasts. Stable on hereditary cancer. Insurance companies continuing to resist Prolaris, for whatever insurance company reasons. Great results would be pointless, because last August still isn't forgiven. It'd be nice to get a little more color on timing of kit-based test timeline, and maybe a teaser on companion diagnostics unrelated to DNA-break repair. General non-event nature of RA biosimilars introduction (and delay, possibly a very long one, on Olumiant) leaves the case for Vectra stronger than anticipated. Non-repeal of Obamacare generally optimistic for Genesight. But again, management announced that they're not pushing for a breakthrough quarter, and with the analysts annoyed, there wouldn't be any point.

    There seems to be enough bearishness around to make a so-so-quarter somewhat positive to the stock price, so next Q will probably average above $20...just not much more than that.

    And for That Guy--Myriad management did everything remotely sensible that you have ever suggested, usually at least a year before you suggested it. concerning less-sensible ideas, I recall well when Quaker Oats used Wilford Brimley as a spokeman, and got burned eventually by his support for cockfighting, among other problems.
  • well done
  • today's news very good as it identifies MYGN as best in class companion diagnostic test
  • United Health Care Contract renewal is important